EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma

Ji Won Han iD, Jeong Won Jang iD

International Journal of Molecular Sciences · 22.07.2023 · 24 (14) · 11799

DOI: 10.3390/ijms241411799 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.07.2023. Verfasst von Ji Won Han und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Basic Science Research Program of the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A combination of atezolizumab with bevacizumab (AB) is the first regimen that has shown superiority compared to sorafenib and is now being used as the systemic treatment of choice for hepatocellular carcinoma (HCC) patients with Barcelona Liver Cancer Clinic stage C. However, a considerable number of patients do not achieve survival or significant responses, indicating the need to identify predictive biomarkers for initial and on-treatment decisions in HCC patients receiving AB. In this manuscript, we summarized the current data from both experimental and clinical studies. This review will be beneficial for both clinicians and researchers in clinical practice as well as those designing experimental, translational, or clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansBevacizumabAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

atezolizmumab-bevacizumabbiomarkerhepatocellular carcinoma

Substanzen

atezolizumabBevacizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea.

ORCID-Profile: Ji Won Han, Jeong Won Jang

Förderung

  • National Research Foundation of Korea
  • Basic Science Research Program of the National Research Foundation of Korea (NRF) funded by the Ministry of Education
  • Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science
  • National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning Korea Bio Grand Challenge Program

Zitieren

APA

Han, J. W., & Jang, J. W. (2023). Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma. International Journal of Molecular Sciences, 24(14), 11799. https://doi.org/10.3390/ijms241411799

Vancouver

Han JW, Jang JW. Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2023;24(14):11799. doi:10.3390/ijms241411799

BibTeX
@article{Han2023,
  author = {Han, Ji Won and Jang, Jeong Won},
  title = {Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {14},
  pages = {11799},
  doi = {10.3390/ijms241411799}
}
Kostenlos starten →